Prior NOAC use associated with lower mortality risk in intracerebral hemorrhage patients
Non-vitamin K antagonist oral anticoagulants (NOACs) appear to be a safer choice than warfarin for intracerebral hemorrhage (ICH) patients on oral anticoagulants, according to a new study co-authored by Ying Xian, MD, PhD, and colleagues at the Duke Clinical Research Institute (DCRI).
Heart patients who take NOACs and subsequently experience ICH may have greater mortality than those who are not on NOACs, according to a new study by DCRI researchers. However, NOACS may still be safer than an older anticoagulant, warfarin.
The study was presented at the 2018 International Stroke Conference in Los Angeles and published simultaneously in JAMA.
NOACs are increasingly prescribed for high-risk patients with atrial fibrillation because they have fewer complications than warfarin. However, they still pose a risk of ICH. Prior to this study, it was unclear if NOAC patients who experienced an ICH were at greater risk of death than patients with no history of NOACs or patients who received warfarin.